Phase 1 study of JNJ-42756493, a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced solid tumors.
2014 ◽
Vol 32
(15_suppl)
◽
pp. 2501-2501
◽
2015 ◽
Vol 33
(15_suppl)
◽
pp. 2545-2545
◽
2012 ◽
Vol 48
◽
pp. 191-192
◽
2015 ◽
Vol 33
(30)
◽
pp. 3401-3408
◽
2014 ◽
Vol 32
(15_suppl)
◽
pp. 11010-11010
◽